The medication is used to treat certain mental/mood disorders such as schizophrenia, depression associated with bipolar disorder. It may also help to decrease hallucinations (hearing/seeing things that are not there).
The group now has 257 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY2003-04, the company added.
Cadila Healthcare Ltd is currently trading at Rs332.50, down by Rs5.5 or 1.63% from its previous closing of Rs338 on the BSE. The scrip opened at Rs340.50 and has touched a high and low of Rs341.95 and Rs332.50 respectively.